학술논문

Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma
Document Type
Report
Source
Immunotherapy. February 2015, Vol. 7 Issue 2, p89, 11 p.
Subject
Acariformes -- Usage -- Health aspects
Allergy desensitization -- Methods
Biological products -- Usage -- Health aspects
Health
Usage
Methods
Health aspects
Language
English
ISSN
1750-743X
Abstract
Aim: A double-blind placebo-controlled study was conducted according to EMA guidelines, to evaluate safety, tolerability and short-term treatment effects of three updosing regimens of Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy. Patients & methods: Forty-eight patients were randomized to groups: A (six weekly doses), B (eight weekly doses) or C (eight doses, two clustered doses over 3 weeks). Results: The most frequent adverse events were local reactions. No serious adverse events were found. Severe systemic reactions were reported more frequently in Group C. Decreased cutaneous responses and increased specific IgGs were shown in all active groups, even within the short-term. Conclusion: Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy in depot presentation exhibited good safety and tolerability. Group A seemed to show the best profile for further clinical development.
Author(s): Dolores Hernández Fernández de Rojas [sup.aff1] , Ignacio Antépara Ercoreca [sup.aff2] , Ana Ponte Tellechea [sup.aff3] , Ethel Ibáñez Echevarría [sup.aff1] , Ignacio Jáuregui Presa [sup.aff2] , Pedro Gamboa [...]